Literature DB >> 23806896

The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Ying Taur1, Eric G Pamer.   

Abstract

PURPOSE OF REVIEW: Many infections of immunocompromised patients originate from the gastrointestinal tract. The pathogenesis of these infections often begins with alteration of the intestinal microbiota. Understanding the microbiota and how it can either cause or prevent infection is vital for the development of more effective prevention and treatment of these infections. This article reviews and discusses recent work providing insight into the intestinal microbiota of these at-risk immunocompromised patients. RECENT
FINDINGS: Studies continue to support the premise that commensal bacteria, largely anaerobic, serve to maintain microbial stability and colonization resistance by preventing overgrowth or domination with more pathogenic bacteria, through interactions within the microbial community and with the host. In patients with immune suppression due to high-dose chemotherapy or hematopoietic stem cell transplantation, disruption of the microbiota through antibiotics as well as impairment of host immunity gives rise to perturbations favoring intestinal domination by pathogenic species, leading to increased bacterial translocation and susceptibility to systemic infection.
SUMMARY: An understanding of the intestinal microbiota and the impact of antibiotics will help to guide our treatment of these gut-originating infections.

Entities:  

Mesh:

Year:  2013        PMID: 23806896      PMCID: PMC4485384          DOI: 10.1097/QCO.0b013e3283630dd3

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  63 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

Review 2.  Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

Authors:  Leonard Leibovici; Mical Paul; Michael Cullen; Giampaolo Bucaneve; Anat Gafter-Gvili; Abigail Fraser; Winfried V Kern
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

Review 3.  Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.

Authors:  S H Zinner
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

4.  Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen.

Authors:  Mizuho Hasegawa; Takashi Yamazaki; Nobuhiko Kamada; Kazuki Tawaratsumida; Yun-Gi Kim; Gabriel Núñez; Naohiro Inohara
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

6.  Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis.

Authors:  Irene Jarchum; Mingyu Liu; Lauren Lipuma; Eric G Pamer
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

Review 7.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

Review 8.  Bacteremia due to viridans streptococci in neutropenic patients: a review.

Authors:  P Y Bochud; T Calandra; P Francioli
Journal:  Am J Med       Date:  1994-09       Impact factor: 4.965

9.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

Authors:  M B Edmond; J F Ober; D L Weinbaum; M A Pfaller; T Hwang; M D Sanford; R P Wenzel
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

10.  The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization.

Authors:  Rosana B R Ferreira; Navkiran Gill; Benjamin P Willing; L Caetano M Antunes; Shannon L Russell; Matthew A Croxen; B Brett Finlay
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

View more
  54 in total

Review 1.  Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation.

Authors:  Tessa M Andermann; Andrew Rezvani; Ami S Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

2.  Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms.

Authors:  Rafael Araos; Albert K Tai; Graham M Snyder; Martin J Blaser; Erika M C D'Agata
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

3.  Diet-induced alterations in gut microflora contribute to lethal pulmonary damage in TLR2/TLR4-deficient mice.

Authors:  Yewei Ji; Shengyi Sun; Julia K Goodrich; Hana Kim; Angela C Poole; Gerald E Duhamel; Ruth E Ley; Ling Qi
Journal:  Cell Rep       Date:  2014-06-19       Impact factor: 9.423

4.  Haematopoietic stem cell transplantation induces severe dysbiosis in intestinal microbiota of paediatric ALL patients.

Authors:  K Lähteenmäki; P Wacklin; M Taskinen; E Tuovinen; O Lohi; J Partanen; J Mättö; K Vettenranta
Journal:  Bone Marrow Transplant       Date:  2017-08-07       Impact factor: 5.483

Review 5.  Intestinal microbiota-related effects on graft-versus-host disease.

Authors:  Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Robert R Jenq
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

Review 6.  The intestinal microbiome and surgical disease.

Authors:  Monika A Krezalek; Kinga B Skowron; Kristina L Guyton; Baddr Shakhsheer; Sanjiv Hyoju; John C Alverdy
Journal:  Curr Probl Surg       Date:  2016-06-14       Impact factor: 1.909

Review 7.  Klebsiella pneumoniae: Going on the Offense with a Strong Defense.

Authors:  Michelle K Paczosa; Joan Mecsas
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

Review 8.  The interplay between the intestinal microbiota and the immune system.

Authors:  Yuk Man Kevin Lei; Lekha Nair; Maria-Luisa Alegre
Journal:  Clin Res Hepatol Gastroenterol       Date:  2014-11-11       Impact factor: 2.947

Review 9.  The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.

Authors:  Sohn Kim; April Covington; Eric G Pamer
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

10.  Fecal microbiome alterations in pediatric patients with short bowel syndrome receiving a rotating cycle of gastrointestinal prophylactic antibiotics.

Authors:  Le Yi Phyo; Kamonnut Singkhamanan; Wison Laochareonsuk; Komwit Surachat; Napasorn Phutong; Kaimook Boonsanit; Piyawan Chiengkriwate; Surasak Sangkhathat
Journal:  Pediatr Surg Int       Date:  2021-06-22       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.